Zacks Investment Research lowered shares of Constellation Pharmaceuticals (NASDAQ:CNST) from a buy rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “Constellation Pharmaceuticals, Inc. operates as a bio-pharmaceutical company. It discovers and develops molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. The company’s lead product candidates consists of CPI-1205, which inhibits enhancer of zeste homolog 2 and CPI-0610, which inhibits bromodomain and extra terminal domain. Constellation Pharmaceuticals, Inc. is based in Cambridge, United States. “
Other equities analysts have also recently issued research reports about the stock. ValuEngine cut shares of Constellation Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, January 24th. Robert W. Baird assumed coverage on shares of Constellation Pharmaceuticals in a research report on Monday, January 28th. They set an outperform rating and a $17.00 target price for the company. Finally, HC Wainwright restated a buy rating and set a $18.00 target price on shares of Constellation Pharmaceuticals in a research report on Friday, January 4th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $17.25.
Shares of NASDAQ CNST opened at $9.30 on Tuesday. Constellation Pharmaceuticals has a 52 week low of $4.01 and a 52 week high of $12.45.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in Constellation Pharmaceuticals by 16.9% during the fourth quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock worth $55,000 after acquiring an additional 1,987 shares during the last quarter. Northern Trust Corp raised its position in Constellation Pharmaceuticals by 12.4% during the fourth quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock worth $204,000 after acquiring an additional 5,624 shares during the last quarter. Dean Capital Investments Management LLC acquired a new position in Constellation Pharmaceuticals during the third quarter worth about $351,000. VHCP Management III LLC acquired a new position in Constellation Pharmaceuticals during the third quarter worth about $449,000. Finally, Sphera Funds Management LTD. acquired a new position in Constellation Pharmaceuticals during the fourth quarter worth about $281,000. Institutional investors own 41.92% of the company’s stock.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
Read More: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.